A morphological and biochemical appraisal of the liver and renal effects of lamivudine on rat pregnancy

Clinical and Experimental Obstetrics and Gynecology

Volumn 33, Issue 4, 2006, Pages 209-212

  Pontes, R D V ^a,c   Amed, A M ^a   Simoes R S ^a   Oliveira Filho, R M ^b   Simoes M J ^a   Kulay Jr , L ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c NONE   (Brazil)

Author keywords

Lamivudine; Pregnancy; RAT; Toxicology

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATININE; LAMIVUDINE; NELFINAVIR; UREA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD SAMPLING; CELL NUCLEUS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; FEEDING; FEMALE; FETUS; FETUS LIVER; HETEROCHROMATIN; HISTOPATHOLOGY; KIDNEY; LIVER; LIVER CELL; MALE; MORPHOLOGY; NONHUMAN; PREGNANCY; RAT; SCANNING ELECTRON MICROSCOPY; UREA BLOOD LEVEL; VASODILATATION;

ANIMALS; ANTI-HIV AGENTS; FEMALE; KIDNEY; LAMIVUDINE; LIVER; PREGNANCY; PREGNANCY, ANIMAL; RATS; RATS, WISTAR;

EID: 33845487310     PISSN: 03906663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Centers for Diseases Control (CDC): "Pneumocystis pneumonia". Los Angeles. Morb Mortal Wkly Rep., 1981, 30, 250.
2. Gottlieb M.S., Schroff R., Shanker H.M., Weisman J.D., Fan P.T., Wolf R.A. et al.: "Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy ho-mossexual men: evidence of a new acquired cellular immunodeficiency". N. Eng. J. Med., 1981, 305, 1425.
3. Masur H., Michekis M.A., Greene J.B., Honorato I, Stouwe R.A., Holzman R.S. et al.: "An outbreak of community-acquired Pneumocistys carinii pneumonia initial manifestation of cellular immune dysfunction". N. Eng. J. Med., 1981, 305, 1431.
4. Fauci A.S., Lane H.C.: "Human immunodeficiency virus (HIV) disease: AIDS and related disorders". In: Isselbacher K.J., Braunwald E., Wilson J.D., Martin J.B., Fauci A.S., Kasper D.L. (eds.). Harrison's Principles of Internal Medicine, 13th edition, New York, McGraw-Hill, 1994, 1566.
5. World Health Organization. Joint United Nations. Program on HIV/AIDS (UNAIDS), 2004. AIDS Epidemic update. Geneva, WHO, 2004.
6. Chouquet C., Burgard M., Richardson S., Rouzioux C., Costagliola D.: "Timing of mother-to-child HIV-1 transmission and diagnosis of infection based on polymerase chain reaction in the neonatal period by a non-parametric method". AIDS, 1997, 11, 1183.
7. Minkoff H.: "Human immunodeficiency virus infection in pregnancy". Obstet. Gynecol., 2003, 101, 797.
8. European Collaborative Study.: "Risk factors for mother-to-child transmission of HIV-I". Lancet, 1992, 339, 1007.
9. Loutfy M.R., Walmsley S.L.: "Treatment of HIV infection in pregnant women: antiret-roviral management options". Drugs, 2004, 64, 71.
10. Minkoff H., Ahdieh L., Watts H., Greenblatt R.M., Schmidt J., Schneider M. et al.: "The relationship of pregnancy to the use of highly active antiretroviral therapy". Am. J. Obstet. Gynecol., 2001, 184, 1221.
11. Connor E.M., Sperling R.S., Gelber R., Kiseley P., Scott G., O'Sullivan M.J.: "Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment". N. Eng. J. Med., 1994, 331, 1173.
12. Mofenson L.M., Lambert J.S., Stiehm E.R., Bethel J., Meyer W.A., Whitehouse J. et al.: "For The Pediatric AIDS Trials Group Study 185 Team. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zi-dovudine". N. Eng. J. Med., 1999, 385.
13. Cooper E.R., Charurat M., Mofenson L., Hanson I.C., Itt J., Diaz C. et al.: "Women and Infants Transmission Group. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission". J. Acquir. Immune. Defic. Syndr., 2002, 29, 484.
14. Tuomala R.E., Shapiro I.E., Mofenson L.M., Bryson Y., Culname M., Hughes M.D. et al.: "Antiretroviral therapy during pregnancy and the risk of an adverse outcome". N. Eng. J. Med., 2002, 346, 1863.
15. Pontes R.D.V., Amed A.M., Simões M.J., Oliveira-Filho R.M., Kulay L. Jr.: "Effect of lamivudine on the rat pregnancy outcome". Int. J. Morphol., 2005, 23, 205.
16. Johnson M.A., Moore K.H., Yuen G.B., Bye A., Pakes G.E.: "Clínical pharmacokinetics of lamivudine". Clin. Pharmacocinet., 1999, 36, 41.
17. Johnson M.A., Horak J., Breuel P.: "The pharmacokinetics of lamivudine in patients with impaired hepatic function". Eur. J. Clin. Pharmacol., 1998, 54, 363.
18. Dienstag J.L., Perrillo R.P., Schiff E.R., Bartholomew M., Vicary C., Rubin M.: "A preliminary trial of lamivudine for chronic hepatitis B infection". N. Engl. J. Med., 1995, 333, 1657.
19. Hamilton J.B., Wolfe J.M.: "The effect of male hormone substance upon birth and prenatal development in the rat". Anat. Rec., 1938, 70, 433.
20. Tietz N.W.: "Clinical Guide of Laboratory Tests". 3rd edition, Philadelphia, WB Saunders, 1995.
21. Bartels H., Böhmer M., Heierli E.: "Serum creatinine determination without protein precipitation". Clin. Chim. Acta., 1972, 37, 193.
22. Roch-Ramel F.: "An enzymic and fluorophotometric method for estimating urea concentrations in nanoliter specimens". Anal. Biochem., 1967, 21, 372.
23. Siegel S.: "Estadística No-Paramétrica". México, Trillas edition, 1975.
24. Dienstag J.L., Goldin R.D., Heathcote E.J., Hann H.W., Woessner M., Stephenson S.L. et al.: "Histological outcome during long-term lamivudine therapy". Gastroenterology, 2003, 124, 105.
25. Schvorer E., Kabissa I., Cotto E., Jouvencel A.C., Babalaud C. et al.: "Lamivudine therapy of chronic hepatitis B in three groups of patients: non transplanted patients, liver recipients and kidney recipients". Gastroenterol. Clin. Biol., 2002, 26, 62.
26. John S., Alkhuja S., Sviglia G.: "Steatosislactic acidosis syndrome associate with sta-vudine and lamivudine therapy (letter)". AIDS. 2000, 14, 1286.
27. Mokrzycki M.H., Harris C., May H., Laut J., Palmisano J.: "Lactic acidosis associated with stavudine administration: a report of five cases". Clin. Infect. Dis., 2000, 30, 198.
28. ter Hofstede H.J., Koopmans P.P., van Haelst U.J.: "Hepatic steatosis during treatment with zidovudine and lamivudine in an HIV-positive patient". Ned. Tijdschr. Ceneeskd., 1998, 142, 415.
29. Savès M., Vandentorren S., Daucourt V., Marimoutoun C., Dupon M., Couzigou P.: "Severe hepatic cytolisis: incidence and risk factors in patients treated by antiretroviral combinations. Acquitaine Cohort, France, 1996-1998. Group d'Epidemiologie Clinique de SIDA en Aquitaine (GECSA)". AIDS. 1999, 13, 115.
30. Travlos G.S., Morris R.W., Elwell M.R., Duke A., Rosenblum S., Thompson M.B.: "Frequency and relationship of clinical chemistry of liver and kidney histopathology findings in 13 week toxicity studies in rats". Toxicology, 1996, 107, 17.
31. Bohjanen P.R., Johnson M.D., Szczech L.A., Wray D.W., Petros W.P., Miller C.R. et al.: "Steadystate pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with end-stage renal disease receiving chronic dialysis". Antimicrob. Agents. Chemother., 2002, 46, 2387.
32. Morris A.A., Baudouin S.V., Snow M.H.: "Renal tubular acidosis and hipophosphataemia after treatment with nucleoside reverse transcriptase inhibitors". AIDS, 2001, 15, 140.
33. Glassok R.J., Cohen A.H., Danovitch G., Parsa K.P.: "Human immunodeficiency virus (HIV) infection and the kidney". Ann. Intern. Med., 1990, 112, 35.
34. Bloom S.L., Dias K.M., Bawdon R.E., Gilstrap L.CIII.: "The maternal-fetal transfer of lamivudine in the ex vivo human placenta". Am. J. Obstet. Gynecol., 1997, 176, 291.
35. Product Information: Epinavir HBV® lamivudine. GlaxoSmithKline, Research Triangle Park, NC. (PI revised 9/2003) reviewed 10/2003.